Skip to content
DataLookout
Menu

NCT03479268

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 17 versions: 15 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 85 words Show 4 more changesShow less
    • Trial completed
    • Primary and study completion dates changed from estimate of Nov 5, 2026 to Oct 28, 2026
    • Secondary endpoints: details revised at 2 of 2 entries
    • Publications: details revised at 1 of 1 entry
  2. Notable Start date: Mar 22, 2018 to Apr 27, 2018v16
  3. Notable Primary and study completion dates: Nov 6, 2025 to Nov 5, 2026v15
  4. Minor Primary and study completion dates: Jun 22, 2025 to Nov 6, 2025v14
  5. Notable Primary and study completion dates: Dec 22, 2024 to Jun 22, 2025v13
Show 9 earlier versionsHide 9 earlier versions
  1. Notable Primary and study completion dates: Jun 22, 2024 to Dec 22, 2024v12
  2. Notable Primary and study completion dates pushed to Jun 22, 2024v11
  3. Notable Primary completion date: Apr 1, 2023 to Dec 1, 2023
    • Study completion date: Apr 2, 2023 to Dec 2, 2023
    v10
  4. Notable Primary completion date: Apr 1, 2022 to Apr 1, 2023v9 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 30 to confirmed 18
    • Study completion date: Apr 2, 2024 to Apr 2, 2023
    • Study sites revised (2)
  5. Notable Lead sponsor: OHSU Knight Cancer Institute to City of Hope Medical Center
    • Study title shortened, about 2 words
    v6
  6. Notable Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 10 to 30
    • Site details revised at 2 of 2 sites
    v5
  7. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 30 to confirmed 10
    • Study description shortened, about 9 words
    • Site details revised at 2 of 2 sites
    v4
  8. Minor Study sites: 1 to 2v3
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 1, 2018 to Mar 22, 2018
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of dose limiting toxicities (DLTs)
Timeframe: Up to 42 days
Incidence of adverse events (AEs), serious AEs (SAEs), dose interruptions, reductions and dose intensity Common Terminology Criteria for Adverse Events version 4.03
Timeframe: Up to 30 days after last course of treatment

Secondary (2)

Overall response rate (ORR) determined based on proportion of participants who achieve complete response (CR), with incomplete marrow recovery (CRi), partial response (PR), or nodular partial response (nPR)
Event-free survival (EFS)

Arms and interventions

Treatment (pevonedistat, ibrutinib)Experimental

Participants receive pevonedistat IV over 1 hour on days 1, 3, and 5, and ibrutinib PO daily on days 2-21 of course 1 and days 1-21 of subsequent courses. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Participants then receive only ibrutinib PO daily on days 1-21. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.

Drugs: Ibrutinib, Pevonedistat

Other: Laboratory Biomarker Analysis, Pharmacokinetic Study, Pharmacological Study

Sites

2 sites in 1 country